HopeStage
Back to all studies
CompletedNCT00429091

Different doses of ABT-894 for ADHD in adults

About this titleRead the official source — NCT00429091

Researchers compared ABT-894, placebo and atomoxetine, tracking side effects to assess safety in adults with ADHD.

Medication studyAges 18–60United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared ABT-894, placebo and atomoxetine, tracking side effects to assess safety in adults with ADHD.

Who was this study for?

This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations
San Francisco and 21 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2007
Recruitment status
Completed
Enrollment listed in the registry
243
Sponsor
Abbott
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT00429091
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

San Francisco · Wildomar · Orlando

19 more locations
  • West Palm Beach
  • Libertyville
  • Overland Park
  • Rockville
  • Boston
  • Okemos
  • Troy
  • Clementon
  • Charlotte
  • Eugene
  • Philadelphia
  • Charleston
  • Austin
  • Bellaire
  • San Antonio
  • Salt Lake City
  • Burlington
  • Virginia Beach
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared ABT-894, placebo and atomoxetine, tracking side effects to assess safety in adults with ADHD.

Who is behind this study?

The study sponsor is Abbott.

Did this study involve medication?

Yes. The study involved medication, including ABT-894, atomoxetine and placebo.

Who was this study for?

This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies